This content is from: Premium Casdin Leads a Biopharma Surge Several funds that lost large amounts last year rebounded nicely in the first month of 2023. By Stephen Taub February 21, 2023
This content is from: Premium Pfizer-Wyeth: It's a chemical reaction Wide spreads lure merger arb players into Pfizer-Wyeth bet. August 24, 2009
This content is from: Portfolio Allergan-Pfizer Merger Gives Pharma a Growth Injection The $160 billion all-stock deal is the largest-ever tax inversion and pharmaceutical sector merger. By Anne Szustek December 16, 2015
This content is from: Portfolio Jack Levy: Strategic Thinking And People Skills 2009 Rainmakers of the Year: Pfizer–Wyeth Corp. merger By Xiang Ji December 16, 2009
This content is from: Premium Perceptive Gets a Big Boost From Pfizer’s Array Deal The healthcare and biotech specialist enjoyed hefty gains in many of its top holdings on Monday. By Stephen Taub June 18, 2019
This content is from: Portfolio The 2015 Hedge Fund Rising Stars: Monica Lai At Pfizer, Lai oversees alternative investments for the pharmaceuticals giant’s $14 billion defined benefit pension plan. By Tyler Davies June 15, 2015
